Or, Chris
Heier, Jeffrey S.
Boyer, David
Brown, David
Shah, Sumit
Alibhai, Agha Yasin
Fujimoto, James G.
Waheed, Nadia
Article History
Received: 23 May 2019
Accepted: 12 August 2019
First Online: 20 August 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: JSH: Financial Support: 4D Molecular Technologies, Acucela, Adverum, Aerie, Aerpio, Allegro, Apellis, Asclepix, Astellas, Bayer, BVI, Coda Therapeutix, Corcept, Daiichi Sankyo, Genentech/Roche, Genzyme, Heidelberg, Hemera, Janssen R&D, Kanghong, Kodiak, Neurotech, Notal Vision, Novartis, Ocular Therapeutix, Ophthotech, Optovue, Quark, Ra Pharmaceuticals, Regeneron, Regenxbio, Scifluor, Shire, Stealth Biotherapeutics, Thrombogenics, TLC, Tyrogenex.NW: Financial Support: Macula Vision Research Foundation, Topcon Medical Systems, Inc., Nidek Medical Products, Inc., Optovue, Inc. (Consultant), Carl Zeiss Meditec, Inc.JF: Optovue, Inc. (Patent, Personal Financial Interest and Consultant), Carl Zeiss Meditec, Inc. (Patent), Topcon Medical Systems, Inc. (Recipient).DBrown: Consultant – Genentech, Roche, Regeneron, Bayer, Novartis, Adverum, Santen, Samsung, Senju, Clearside Biomedical, Heidelberg, Optos, Zeiss, OHR, Regenxbio, ChengduKanghong Biotechnology, Apellis, Stealth Biotherapeutics; Grants/grants pending – Genentech, Roche, Regeneron, Clearside Biomedical, Heidelberg, Adverum, Novartis, OHR, Santen.DBoyer: Consulting fee – Genentech; Consulting fee or honorarium – OptoVue, Regeneron, Roche, Novartis, Alcon, Allergan, Bayer; Lecture fees – Allergan.